Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Lotte Chemical Titan Tbk (FPNI.JK)
Jakarta, JK, ID
PT Lotte Chemical Titan Tbk, together with its subsidiaries, engages in the production and distribution of polyethylene products in Indonesia. The company produces linear low density polyethylene resins used in film, wire and cable, rotational molding, and others extrusion applications; high density polyethylene resins used in injection and blow molding, extrusion, and film applications; low density polyethylene with applications, including food packaging films, heavy duty bags, injection molded articles and container lids; and polypropylene homopolymers, and polypropylene random and impact copolymers, as well as BOPP films. It also involved in the trading and importation of polyethylene and polypropylene, as well as trading of rubber and plastics in basic form. The company was formerly known as P.T. Titan Kimia Nusantara Tbk and changed its name to PT Lotte Chemical Titan Tbk in April 2013. PT Lotte Chemical Titan Tbk was incorporated in 1987 and is headquartered in Jakarta, Indonesia. PT Lotte Chemical Titan Tbk is a subsidiary of Lotte Chemical Titan International Sendirian Berhad.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | +8.28% | -25.91% | -31.59% | -60.00% | -60.43% | +75.96% | +81.19% | +60.53% | +212.82% | -26.06% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Chemicals - Specialty: +7.2%-2.2% Q1'26: -6.2% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +16.5%-1,400.0% Q1'26: +200.0% (vs Q1'25)
-
FCF margin Chemicals - Specialty: +27.4%-2.3% Q1'26: -11.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +9.5%-3.0% Q1'26: +2.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +6.2%-9.7% Q1'26: +9.8% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Chemicals - Specialty: 0.21×-0.04× Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-14 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-13 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-10 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Calvin Wiryapranata | Chief Financial Officer & Director | — | male |
| Evan Kusuma Brata | Corporate Secretary | — | male |
| Kyoungyoon Choi | President Director | — | male |
| Risa Alex Wibowo | Head of Audit Internal Unit | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FPNI.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
